The U.S. Food and Drug Administration has approved a low-cost preventive treatment for HIV, designed by Dr Reddy’s Laboratories. This drug, lenacapavir, will be available for 40 dollars a year in 120 countries, facilitating access in low-income regions. The initiative aims to bridge the gap between medical innovation and access to care, addressing an urgent need in the fight against HIV.